Emerald Bioscience Inc. (OTCMKTS:EMBI – Get Free Report)’s stock price reached a new 52-week high on Monday . The company traded as high as $13.75 and last traded at $13.40, with a volume of 6142 shares traded. The stock had previously closed at $12.00.
Emerald Bioscience Stock Performance
The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $3.69 billion, a price-to-earnings ratio of -167.50 and a beta of 0.43. The stock’s 50 day moving average price is $7.94 and its two-hundred day moving average price is $4.39.
About Emerald Bioscience
Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.
Featured Stories
- Five stocks we like better than Emerald Bioscience
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Mid-Cap Stocks to Outperform the Market This Cycle
- What Are Dividend Champions? How to Invest in the Champions
- How and When to Roll Your Options Positions?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Low VIX? 3 High Beta Stocks To Boost Your Returns
Receive News & Ratings for Emerald Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emerald Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
